|
Sartorius Stedim Biotech SA / Key word(s): Dividend/AGM/EGM Board of Directors of Sartorius Stedim Biotech resolves to propose a dividend of 0.69 euros per share to the Annual Shareholders’ Meeting 07-Feb-2024 / 17:30 CET/CEST Aubagne, February 7, 2024
Board of Directors of Sartorius Stedim Biotech resolves to propose a dividend of 0.69 euros per share to the Annual Shareholders’ Meeting The Board of Directors of Sartorius Stedim Biotech S.A. resolved at today’s meeting to submit a proposal to the combined Annual Shareholders’ Meeting to be held on March 26, 2024, to pay a dividend of 0.69 euros per share for fiscal 2023. Under this proposal, the total distributed profit would be 67.1 million euros. The dividend will be paid on April 4, 2024. The Board of Directors also approved the decision to submit to the Annual Shareholders’ Meeting the 2023 results of Sartorius Stedim Biotech which had already been published on a preliminary basis on January 26, 2024. This press release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events. Sartorius Stedim Biotech shall not assume any liability for the correctness of this release. The original French press release is the legally binding version. Financial calendar A profile of Sartorius Stedim Biotech Contact Attachment File: Media Release Dissemination of a Financial Wire News, transmitted by EQS Group. |
Monthly IV version of Leqembi set for FDA review by next year – Pharmaceutical Technology
Leqembi won full FDA approval last July as a 100mg/mL injection for intravenous (IV) use as Eisai and Biogen pursue a monthly dosing regimen. Image
June 10, 2024